A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(TM) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) in Patients With Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma of the Urothelium
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Paclitaxel (Primary)
- Indications Bladder cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Achieve Life Sciences; Sonus Pharmaceuticals
- 01 Aug 2017 According to Achieve Life Sciences media release, Achieve Life Sciences merged with OncoGenex Pharmaceuticals and the later changed its name to Achieve Life Sciences.
- 08 Jun 2010 There are currently 44 patients on study with accrual ongoing, according to information presented at ASCO 2010.
- 09 Jun 2009 OncoGenex Pharmaceuticals added as trial sponsor and trial affiliate as reported by ClinicalTrials.gov.